Fortress Diagnostics
Fortress Diagnostics is a UK-based in vitro diagnostics manufacturer founded in 2000, producing 1,000+ clinical diagnostic test kits across immunoassay, molecular, rapid and clinical chemistry formats from its ISO 13485-accredited Antrim facility, distributed through a network covering 100+ countries.
- Company typePrivate
- Founded2000
- HeadquartersAntrim, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Fortress Diagnostics does
Fortress Diagnostics is a UK-based in vitro diagnostics (IVD) manufacturer founded in 2000 and headquartered in Antrim, Northern Ireland. The company designs, develops and manufactures clinical diagnostic test kits across clinical chemistry, immunoassay (ELISA and CLIA), molecular diagnostics (RT-qPCR), rapid lateral-flow tests, haematology, haemostasis/coagulation, blood grouping, urinalysis and infectious disease panels (HIV, hepatitis, COVID-19, tuberculosis, syphilis, febrile antigens). Manufacturing is consolidated in a 30,000 sq ft ISO 13485:2016-accredited facility equipped with freeze-drying, specialist manufacturing and automation capabilities, and the portfolio spans more than 1,000 products.
The business sells primarily through an international distributor network covering over 100 countries across five continents, including difficult-to-serve markets such as Libya, Yemen, Iraq, Afghanistan, Haiti and Djibouti. In the UK it supplements distribution with direct sales representatives targeting private hospitals, GPs, clinics, pharmacies and universities, and with channel partners such as Una Health. Revenue streams consist of one-time reagent and consumable sales, instrumentation hardware (the Monarch 240/400/800 clinical chemistry analysers), and lower-volume recurring income from ESfEQA External Quality Assessment subscriptions. R&D intensity is high, with the company reinvesting approximately 30% of annual turnover and maintaining multi-university research partnerships with Queen's University Belfast, University of Nottingham, University of Cape Town and Ulster University.
The company's commercial identity was sharpened by the COVID-19 period: it rapidly launched RT-qPCR, antibody ELISA, IgM/IgG rapid and antigen rapid tests, with the lateral-flow product selected by Imperial College London for the REACT 2 national seroprevalence programme. Fortress has accumulated multiple industry awards including IVD Product Manufacturer of the Year - UK (2024), GHP Best IVD Development and Manufacturing Company (2021) and Belfast Telegraph SME Healthcare Business of the Year (2019), and continues to operate an active global distributor recruitment and product launch programme through 2026.
Fortress Diagnostics firmographics
Firmographics- Name
- Fortress Diagnostics
- Legal name
- Fortress Diagnostics
- Website
- https://fortressdiagnostics.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Fortress Diagnostics is a UK-based in vitro diagnostics manufacturer founded in 2000, producing 1,000+ clinical diagnostic test kits across immunoassay, molecular, rapid and clinical chemistry formats from its ISO 13485-accredited Antrim facility, distributed through a network covering 100+ countries.
- Ownership category
- akta.pro rank
Fortress Diagnostics industry classification
Industry- Product category
- In Vitro Diagnostics (Clinical Diagnostics Manufacturing)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industries
- Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where Fortress Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Antrim
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Fortress Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- IVD Reagents and Test Kits: Fortress Diagnostics manufactures and sells an extensive portfolio of clinical diagnostic tests including clinical chemistry reagents, analyser specific reagents, haematology reagents, haemostasis products, immunoassay ELISA and CLIA tests, rapid tests, and molecular diagnostics. Products are sold to laboratories, hospitals, clinics, blood banks and research institutions globally through their distribution network.
- Quality Controls and Calibrators: The company manufactures and sells quality control materials and calibrators for various diagnostic parameters including tumour markers, cardiac markers, diabetes markers, and infectious disease testing to ensure laboratory assay reliability.
- Instrumentation: Sale of clinical chemistry analysers including the Monarch 240, Monarch 400, and Monarch 800 models for automated random access testing.
- IQC & EQA Programmes: Through partnership with ESfEQA, Fortress offers laboratories participation in internationally recognised External Quality Assessment programs enabling comparison of results with other laboratories.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Custom quote-based pricing for all products |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Fortress Diagnostics product offering
Product offeringCore offering
Fortress Diagnostics develops, manufactures and supports an extensive portfolio of in vitro diagnostic (IVD) clinical test kits, reagents, quality controls and clinical chemistry analysers from its ISO 13485:2016-accredited facility in the United Kingdom. Its products span ELISA and CLIA immunoassays, rapid point-of-care tests, RT-qPCR molecular diagnostics, clinical chemistry, haematology, haemostasis, blood grouping, serology and urinalysis, and are sold through distributors to hospital laboratories, clinics, blood banks and research institutions in over 100 countries.
Product overview
Fortress Diagnostics is an in vitro diagnostics (IVD) company offering an extensive portfolio of clinical diagnostic products manufactured in its ISO 13485:2016-accredited UK facility. The product range includes Clinical Chemistry Reagents and Analyser-Specific Reagents for automated platforms, Controls & Calibrators for quality assurance, Immunoassay ELISA and CLIA tests for protein/hormone/antibody detection, Rapid Tests for point-of-care screening, and Molecular Diagnostics (RT-PCR) for pathogen detection. Key testing categories span Haematology, Haemostasis/Coagulation, Blood Grouping, Urinalysis, Infectious Diseases (HIV, Hepatitis, COVID-19, Tuberculosis), Tumour Markers, and Food & Feed Safety. The company also offers Instrumentation including the Monarch series of clinical chemistry analysers, and supports laboratory quality through IQC & EQA programmes. Products are distributed to over 100 international markets through a global distribution network.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Chemistry Reagents
Quantifiable outcome
- 98.6%+ accuracy demonstrated for COVID-19 antigen tests
- +3 more outcomes
Companies that use Fortress Diagnostics
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
Fortress Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
Fortress Diagnostics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, minor and flagship.
- Una HealthcoreUK distribution partnership for delivery of Fortress Diagnostics COVID-19 products. Una Health is a family-run business with proven track record in customer service and technical support. The partnership enabled delivery of validated COVID-19 tests validated by Porton Down.
- Ulster UniversityminorRecent R&D partnership announced as part of ongoing collaboration with universities for test development in tuberculosis and cancer diagnostics.
- Imperial College LondonflagshipFortress Diagnostics' COVID-19 Rapid Antibody Test was selected as 'the most suitable candidate' for the National Coronavirus Disease 2019 Seroprevalence Programme (REACT 2). The study, funded by the Department of Health and Social Care and commissioned by Imperial College London, is conducted in partnership with Imperial College Healthcare NHS Trust and Chelsea and Westminster NHS Foundation Trust. Fortress tests were used for nationwide antibody surveillance across England.
- University of NottinghamcoreR&D partnership for joint development of new tests for TB and lung cancer. Development projects completed and manufacturing is underway. TB test already exported to South Africa. University collaboration enables access to research expertise and academic resources.
- University of Cape TowncoreR&D partnership for joint development of new tests for TB and lung cancer. Collaboration with African university supports development of diagnostics relevant to regional health priorities.
- Queen's University BelfastcoreR&D partnership for development of diagnostic tests including early cancer detection. Proximity to headquarters enables close collaboration with academic researchers in Northern Ireland.
- ESfEQA (European Society for External Quality Assessment)corePartnership enables Fortress Diagnostics to offer laboratories participation in internationally recognised External Quality Assessment (EQA) programmes. These programmes allow laboratories to compare results with other laboratories to maintain and improve analytical performance quality. Fortress selected the Clinical Chemistry program (31 analytical parameters) and Infectious Disease Program (anti-HIV, anti-HCV, anti-HBc and HBsAg) for the launch, with additional programs available upon request.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Fortress Diagnostics competitors and assessment
Company assessmentDirect peers
- Trinity Biotech: Trinity Biotech is a comparable mid-cap IVD company focused on clinical chemistry, haemostasis, infectious-disease ELISA, and point-of-care diagnostics — overlapping with multiple Fortress product lines and a similar scale profile.
- EKF Diagnostics: EKF is a UK-headquartered mid-cap IVD company offering point-of-care haemoglobin, HbA1c, and clinical chemistry products, comparable in scale, geography, and channel-distribution profile to Fortress.
- Bio-Rad Laboratories: Bio-Rad is a global IVD and life-science research company with overlapping portfolios in clinical chemistry quality controls, immunoassays, blood typing reagents, and molecular diagnostics — closely mirroring Fortress's product breadth and laboratory-customer focus.
- DiaSorin: DiaSorin is an Italian-headquartered specialty IVD company focused on CLIA chemiluminescence immunoassays and molecular diagnostics — a tight competitor in the same assay platforms Fortress highlights as differentiators.
- SD Biosensor: SD Biosensor is a global rapid-diagnostics manufacturer with strong emerging-market reach in HIV, malaria, and COVID-19 lateral-flow tests, comparable to Fortress's rapid-test franchise and emerging-market distribution model.
- Randox Laboratories: Headquartered in Northern Ireland (Crumlin, Co. Antrim), Randox is a direct competitor offering an overlapping portfolio of clinical chemistry reagents, immunoassays, quality controls, and infectious-disease IVDs, and shares Fortress's UK-base, export-heavy, multi-discipline IVD business model.
- QuidelOrtho: QuidelOrtho specialises in rapid lateral-flow diagnostics and clinical laboratory immunoassays (including infectious disease and women's health), directly comparable to Fortress's rapid-tests and immunoassay ELISA/CLIA franchises.
Broad incumbents
- Roche Diagnostics: Roche operates the cobas and Elecsys platforms in immunoassay and clinical chemistry, the dominant global IVD incumbent, and competes with Fortress across reagent menus and analyser placements.
- Hologic: Hologic is a larger diagnostics player with rapid molecular and immunoassay franchises (e.g., Panther, Aptima) that overlap with Fortress's molecular and infectious-disease testing portfolio.
- Abbott Diagnostics: Abbott is a global diagnostics incumbent offering Architect/Alinity immunoassay and clinical chemistry systems with extensive reagent menus — overlapping with Fortress's immunoassay and analyser-specific reagent categories.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Fortress Diagnostics social profiles
Digital presenceFortress Diagnostics compliance and trust
Trust signalCompliance6 records
Fortress Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fortress Diagnostics leadership team
Management profileNumber of profiles
Profiles3 records
Fortress Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fortress Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fortress Diagnostics
What does Fortress Diagnostics do?
Fortress Diagnostics develops, manufactures and supports an extensive portfolio of in vitro diagnostic (IVD) clinical test kits, reagents, quality controls and clinical chemistry analysers from its ISO 13485:2016-accredited facility in the United Kingdom. Its products span ELISA and CLIA immunoassays, rapid point-of-care tests, RT-qPCR molecular diagnostics, clinical chemistry, haematology, haemostasis, blood grouping, serology and urinalysis, and are sold through distributors to hospital laboratories, clinics, blood banks and research institutions in over 100 countries.
Is Fortress Diagnostics a public or private company?
Fortress Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Fortress Diagnostics founded?
Fortress Diagnostics was founded in 2000. It employs 51 to 100 people.
Where is Fortress Diagnostics based?
Fortress Diagnostics is headquartered in Antrim, United Kingdom, in the Europe region.
How does Fortress Diagnostics make money?
Four revenue lines are on record. IVD Reagents and Test Kits are the primary driver. The others are quality Controls and Calibrators, instrumentation and IQC & EQA Programmes.
Who are Fortress Diagnostics's main competitors?
Direct peers on record are Trinity Biotech, EKF Diagnostics, Bio-Rad Laboratories, DiaSorin, SD Biosensor, Randox Laboratories and QuidelOrtho. Broad incumbents are Roche Diagnostics, Hologic and Abbott Diagnostics.
Does Fortress Diagnostics have an API?
No public API is recorded for Fortress Diagnostics.
What industry is Fortress Diagnostics in?
Fortress Diagnostics's product category is In Vitro Diagnostics (Clinical Diagnostics Manufacturing). Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAHAAAL, Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables). Its NAICS code is 325413 and its SIC code is 2835.